Liquid Biopsy Presentations and Case Studies

Liquid biopsy has been gaining traction within cancer research as a complementary or alternative technique to solid tissue biopsy due to a few factors:

  • Less invasive procedure enabling sampling at multiple time points to monitor progression of the cancer
  • Better representation of tumor heterogeneity
  • Faster turnaround time from sample to results
  • Lower costs compared with traditional tissue biopsies

Hear what your peers are doing in liquid biopsy through the testimonials, videos, case studies, and more below. 

Video: Variant detection in cell-free DNA from NSCLC using NGS

Dr. Tracy Stockley; Associate Director, Molecular Diagnostics Division; Princess Margaret Cancer Center

  • Dr. Tracy Stockley presents the utilization of NGS and cell-free DNA for detection of EGFR T790M resistance mutation
  • Focuses on mutation detection in cell-free DNA and comparison with droplet digital PCR technology


Detection of rare mutations like EGFR T790M down to 0.14% AF


“Using the Oncomine Lung cfDNA Assay, we were able to amplify more difficult samples.  The assay allowed us the detection of mutations like EGFR T790M down to 0.14% allelic fraction.”

—Dr. Jose Luis Costa, Senior Researcher, Institute of Molecular Pathology and Immunology of the University of Porto, Portugal

Detection of genomic heterogeneity in metastatic colorectal cancer samples


“Genomic heterogeneity after anti-EGFR therapy was successfully detected in 94% of the research metastatic colorectal cancer samples using a next-generation sequencing multibiomarker approach. The Oncomine Colon cfDNA Assay enabled detection of somatic mutations with MAF >0.1%.”

—Dr. Bea Bellosillo, Head of Section, Hospital del Mar, Spain

Case studies

An international multi-center study evaluates use of cfDNA for tracking tumor heterogeneity and evolution in lung cancer

  • Dr. Nicola Normanno presents the results of an international multi-center study
  • Focuses on tumor heterogeneity and evolution that could change treatment decisions in the future

Mutational analysis of cfDNA in a lung tumor

  • Dr. José Luis Costa presents data obtained running cfDNA from plasma samples on the Ion S5 System
  • Focuses on expected results from a research study monitoring a lung tumor